Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

Like Alnylam, Regeneron has recently reconfigured a long-standing R&D collaboration in the area of immuno-oncology, having previously decided to go their separate ways in a broader antibody alliance

Latest news

More from news
Approximately 69 fully matching, plus 266 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However, the company continues to study Opdivo in trials twinned with a very wide range of novel agents, with the hope of finding a combination which can take immuno-oncology (IO)

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    By Chris Learn and Martin Lachs. The immuno-oncology (IO) field is becoming incredibly crowded and competitive. ... Chris Learn is Program Manager and Martin Lachs is VP Project Management, both at Oncology Haematology, ICON plc.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Merck/MSD looks to have gained a dominant position in checkpoint

  • Is China ready for a pharmaceutical gold rush?

    China has long been a leader in pharmaceutical manufacturing and export.But with the news that the country has approved its first immuno- oncology (I-O) treatment comes the hope that ... Professor Yi-Long Wu, a tenured director of Guangdong General

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... So that’s the rationale behind

More from intelligence
Approximately 3 fully matching, plus 52 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 18 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics